David S. Ege - Feb 4, 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
Executive Vice President and Chief Technology Officer
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for David Ege
Stock symbol
MCRB
Transactions as of
Feb 4, 2022
Transactions value $
$0
Form type
4
Date filed
2/8/2022, 08:30 PM
Next filing
Jul 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MCRB Stock Option (Right to Buy) Award $0 +175K $0.00 175K Feb 4, 2022 Common Stock 175K $7.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

Executive Vice President and Chief Technology Officer